Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Axsome Therapeutics, Inc. (AXSM), covering cash flow, earnings, and balance sheets.
Axsome Therapeutics, Inc. (AXSM) Income Statement & Financial Overview
Explore comprehensive income reports for Axsome Therapeutics, Inc. AXSM, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $121.46M | $118.77M | $104.76M | $87.17M |
| Cost of Revenue | $9.79M | $10.51M | $8.44M | $8.05M |
| Gross Profit | $111.67M | $108.25M | $96.33M | $79.11M |
| Gross Profit Ratio | $0.92 | $0.91 | $0.92 | $0.91 |
| R&D Expenses | $44.78M | $55.25M | $45.39M | $49.85M |
| SG&A Expenses | $120.79M | $113.27M | $95.56M | $103.55M |
| Operating Expenses | $168.66M | $181.29M | $158.95M | $157.16M |
| Total Costs & Expenses | $178.44M | $189.97M | $167.39M | $165.21M |
| Interest Income | $0.00 | $4.74M | $0.00 | $0.00 |
| Interest Expense | -$2.43M | $6.95M | $1.98M | $1.30M |
| Depreciation & Amortization | $4.86M | $2.07M | $2.06M | $1.99M |
| EBITDA | -$56.98M | -$70.54M | -$60.56M | -$78.05M |
| EBITDA Ratio | -$0.47 | -$0.59 | -$0.58 | -$0.90 |
| Operating Income | -$56.98M | -$72.62M | -$62.62M | -$78.05M |
| Operating Income Ratio | -$0.47 | -$0.61 | -$0.60 | -$0.90 |
| Other Income/Expenses (Net) | -$2.43M | -$2.21M | -$1.98M | -$1.30M |
| Income Before Tax | -$59.41M | -$74.83M | -$64.60M | -$79.34M |
| Income Before Tax Ratio | -$0.49 | -$0.63 | -$0.62 | -$0.91 |
| Income Tax Expense | $0.00 | $85000.00 | $0.00 | $0.00 |
| Net Income | -$59.41M | -$74.91M | -$64.60M | -$79.34M |
| Net Income Ratio | -$0.49 | -$0.63 | -$0.62 | -$0.91 |
| EPS | -$1.22 | -$1.54 | -$1.34 | -$1.67 |
| Diluted EPS | -$1.22 | -$1.54 | -$1.34 | -$1.67 |
| Weighted Avg Shares Outstanding | $48.87M | $48.54M | $48.14M | $47.57M |
| Weighted Avg Shares Outstanding (Diluted) | $48.87M | $48.54M | $48.14M | $47.57M |
The company's financials show resilient growth, with revenue advancing from $87.17M in Q2 2024 to $121.46M in Q1 2025. Gross profit remained healthy with margins at 92% in Q1 2025 compared to 91% in Q2 2024. Operating income hit -$56.98M last quarter, sustaining a consistent -47% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$56.98M. Net income rose to -$59.41M, while earnings per share reached -$1.22. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan